New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:25 EDTBA, BA, LLY, LLYSenate Judiciary Committee to hold a hearing
The Subcommittee on Crime and Terrorism holds a hearing entitled, "Economic Espionage and Trade Secret Theft: Are Our Laws Adequate for Today’s Threats? with Vice President Paul Hoffman of The Boeing Company and Vice President Doug Norman of Eli Lilly & Company on May 13 at 2:30 pm. Webcast Link
News For BA;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
06:10 EDTBALufthansa publishes timetable in response to VC planned strike
Subscribe for More Information
October 17, 2014
11:58 EDTBATextron rallies after better than expected Q3 EPS, raising FY14 profit outlook
Shares of aircraft and defense company Textron (TXT) are advancing after the firm reported better than expected third quarter earnings per share and raised its profit outlook for fiscal 2014. WHAT'S NEW: Textron this morning reported Q3 EPS from continuing operations of 57c and revenue of $3.43B, compared to consensus of 52c and $3.63B, respectively. Aviation revenue for the quarter came in at $1.08B, Bell revenue was $1.18B, Systems revenue was $358M, Industrial revenue was $785M and Finance revenue was $25M for the quarter. Chief Executive Officer Scott Donnelly said commented that the increased revenues at Aviation, Industrial and Bell primarily reflected the success of its new product investment and acquisition strategies. Donnelly said the company achieved significant margin improvement in the quarter at Textron Aviation, which reflected higher volumes and better performance. Bell also had improved performance in Q3, Donnelly said, leading to an increase in quarterly margins compared to last year. WHAT’S NOTABLE: The company raised its FY14 EPS from continuing operations view to $2.05-$2.15 from $1.92-$2.12, in line with analysts' consensus estimates of $2.07. Textron also raised its FY14 outlook for cash flow from continuing operations of the manufacturing group before pension contributions to $700M-$800M, with expected pension contributions of around $83M. On the company's earnings conference call, management said it saw a pickup of orders in September and October in the new aircraft market. The company said it is also seeing significant contributions from its M&A investments. PRICE ACTION: In late morning trading, Textron rose $4.16, or about 12.4%, to $37.82 on heavy trading volume. Including today’s advance, the stock has gained approximately 36% over the past twelve months. OTHERS TO WATCH: Other companies in the aircraft and defense business include Boeing (BA), up 2.6%, Spirit Aerosystems (SPR), up 3.8%, and Embraer SA (ERJ) up 3.9%.
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
07:32 EDTBABoeing volatility elevated into Q3 and outlook
Subscribe for More Information
07:31 EDTBAEMC volatility elevated into Q3 results and outlook
EMC October weekly call option implied volatility is at 51, November is at 34, January is at 27; compared to its 26-week average of 23 into the expected release of Q3 results on October 22.
October 16, 2014
14:36 EDTLLYLilly to close Guayama facility, will take 16c charge in Q4
Eli Lilly announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. All of the approximately 100 full-time non-contracted employees currently working in Guayama will be offered employment at Lilly's Carolina, Puerto Rico, location. As a result of this action, the company expects to record a charge of approximately $170M or approximately 16c per share, after tax, in Q414. While Lilly will initiate efforts to sell the Guayama site, the company will continue to invest in two manufacturing plants at Carolina. In November 2013, Lilly announced a $200M investment to increase capacity in its Carolina-based insulin active ingredient manufacturing plant. In July, Lilly announced an additional $40M in investments to increase capabilities at its Carolina-based drug product site as part of a rebalancing of Lilly's oral solid dosage network.
13:03 EDTBABoeing reports one new 747 order in weekly update
Subscribe for More Information
06:28 EDTBABoeing mulls potential helicopter deal with Brazilian Army, Reuters says
Boeing said that the Brazilian Army has shown an interest in purchasing a few of the company's CH-47 Chinook helicopters, and explained that it maintains its opinion that Brazil is a noteworthy collaborator for projects in the defense and commercial space, according to Reuters, citing comments from Boeing spokesman Scott Day. Reference Link
October 14, 2014
07:15 EDTLLYBiotech Industry Organization to hold a summit
Subscribe for More Information
October 13, 2014
14:29 EDTBABoeing begins production on first 737 MAX parts
Boeing has started production of the first 737 MAX fuselage stringers at Boeing Fabrication Integrated AeroStructures in Auburn, Wash. Stringers run the length of the fuselage structure giving it stability and strength. After forming, Boeing will send the stringers to Spirit Aerosystems in Wichita, Kan. for incorporation into the first 737 MAX fuselage. From there the fuselage will be shipped to Boeing's Renton, Wash. facility where Boeing employees will build the 737 MAX. The program is on track to begin final assembly of the first 737 MAX in 2015. The airplane will be part of the flight test fleet and is scheduled to fly in 2016. The 737 MAX incorporates the latest technology CFM International LEAP-1B engines, Advanced Technology winglets and other improvements to deliver the highest efficiency, reliability and passenger comfort in the single-aisle market. The 737 MAX will be 14% more fuel-efficient than today's most efficient Next-Generation 737s – and 20% better than the original Next-Generation 737s when they first entered service.
10:17 EDTBAEbola related weakness in aerospace stocks seen as buying opportunity
Subscribe for More Information
07:26 EDTBACommercial aerospace stocks should be bought on any weakness, says Wells Fargo
Subscribe for More Information
October 12, 2014
19:41 EDTBABoeing and Garuda Indonesia announce $4.9B order
Subscribe for More Information
October 10, 2014
18:51 EDTBADOJ orders Boeing to pay $23M to resolve False Claims Act allegations
Subscribe for More Information
10:03 EDTLLYEli Lilly olaratumab granted orphan designation as soft tissue sarcoma treatment
Subscribe for More Information
October 9, 2014
13:56 EDTBAObama calls on Congress to lift defense spending cuts, Politico says
Subscribe for More Information
06:22 EDTBACFM launches next phase of testing for LEAP engine
CFM International's LEAP engine took the skies for the first time on October 6 on a modified 747 flying testbed at GE Aviation Flight Test Operations in Victorville, California, launching the next phase of testing for the advanced engine program. The engine behaved well and completed multiple aeromechnical test points at various altitudes during the nearly three-hour first flight. Over the next several weeks, the engine will complete a comprehensive test schedule that will gauge engine operability, stall margin, performance, and acoustics. The LEAP-1A/-1C variants are on track for engine certification in 2015. The total program, which encompasses all three LEAP engine variants, includes 28 ground and CFM flight test engines, along with a total of 32 flight test engines for Airbus (EADSY), Boeing (BA), and COMAC. Although all three LEAP engine variants will fly on the modified testbed, the configuration currently being tested is a fully integrated propulsion system. CFM is a joint venture between GE (GE) and France's Safran. Reference Link
October 8, 2014
10:55 EDTLLYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
08:19 EDTBAAerCap reports 134 aircraft transactions completed during Q3
AerCap Holdings (AER) announced the completion of 134 aircraft transactions during Q3. Signed lease agreements for 84 aircraft. Delivered 26 aircraft under contracted lease agreements. Purchased nine new aircraft, including five Boeing (BA) 787-8s, three Boeing 737-800s and one Airbus (EADSY) A321-200. Executed sale and part-out transactions for 15 aircraft, including: one Airbus A300-600F, one Airbus A340-300, eight Boeing B737 classics, one Boeing B767-300ER and two MD-11s from AerCap's owned portfolio. One Boeing 737 classic and one Airbus A320-200 from AerCap's managed portfolio. Signed financing transactions for $1.5B, including the previously announced private offering of $800M. The total financing transactions completed year-to-date amount to $8.9B.
06:11 EDTLLYNovartis says expects three executive committee members to leave
Novartis (NVS) confirmed that following completion of the transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company (LLY) in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis. The expected changes to the ECN are subject to the closing of the transactions announced on April 22 - Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its Animal Health Business to close in the first quarter of 2015. George Gunn, currently Division Head, Novartis Animal Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. Upon closing of the Animal Health transaction with Lilly he will leave the ECN. Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare, effective at closing of the transaction. Andrin Oswald, currently Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities following closing of the transaction with GSK.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use